Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Novartis’ Tekturna Be Buoyed By Category Captainship?

Executive Summary

The performance of Novartis' newly approved hypertension therapy Tekturna will be a good test of the company's "category captainship" program, which has focused on establishing Novartis as a leader in targeted disease areas

You may also be interested in...



Novartis Gets By With A Little Help From Its Hypertension Franchise

Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call

Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June

Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)

Novartis Forging Ahead: Exforge Gets Full Approval, To Launch By End Of June

Novartis will launch its hypertension treatment Exforge by the end of the month following FDA final approval of the product. The drug is the first to combine an angiotensin receptor blocker, Novartis' Diovan (valsartan), with a calcium channel blocker, Pfizer's Norvasc (amlodipine)

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel